BioCryst Pharmaceuticals, Inc. (BCRX) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for BioCryst Pharmaceuticals, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | 6.20x | -17.49x | -5.08x | -8.64x | -13.48x | -6.82x |
| P/B Ratio | -13.74x | -3.27x | -2.53x | -7.24x | -23.19x | -64.69x |
| P/S Ratio | 1.87x | 3.45x | 3.47x | 7.88x | 15.78x | 69.96x |
| Profitability | ||||||
| Gross Margin | 97.8% | 97.2% | 98.6% | 97.6% | 95.4% | 90.6% |
| Operating Margin | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% | -981.1% |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% |
| EBITDA Margin | 39.7% | 2.8% | -35.1% | -53.1% | -77.5% | -940.7% |
| Liquidity | ||||||
| Current Ratio | 2.06x | 2.63x | 3.31x | 4.90x | 5.46x | 3.06x |
| Quick Ratio | 2.03x | 2.58x | 3.12x | 4.63x | 5.31x | 3.00x |
| Leverage | ||||||
| Debt/Equity | -4.01x | -1.77x | -1.81x | -2.52x | -5.55x | -14.51x |
YoY = year-over-year change. Source: FMP..